This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Learn the scenarios where index funds outperform target date funds, with emphasis on fees, control, and asset allocation flexibility.
26,348 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
As AI reshapes energy, manufacturing, and city grids, one infrastructure stock quietly stands out. Learn why this cri...
Microsoft’s latest earnings show a resilient AI-powered expansion, with a $627 billion backlog and a near $37 billion...
Two AI security stalwarts are racing for the top spot in the cyber defense era. This guide breaks down CrowdStrike vs...
As of July 16, 2026, Brent crude sits around $84.64 per barrel, easing slightly after yesterday’s pullback. The curre...
Microsoft CEO Satya Nadella charts a pragmatic path for enterprise AI: keep data within your own boundary, govern wit...
The Digital Chamber launches the Prediction Markets Working Group to win federal oversight for prediction markets, se...
RE/MAX reports a rise in 2025 net income to $8.2 million, driven by growth outside the U.S. even as U.S. agent counts...
Workday posted a solid Q4 beat on earnings and revenue, yet forward guidance disappointed investors. Shares tumbled a...
Carl Icahn’s latest stake move in Icahn Enterprises drew attention from investors. This article breaks down what icah...
Home Depot and Lowe's are racing to harness AI to sharpen pricing, streamline operations, and boost customer experien...
As earnings season winds down, March can be a smart time to add leading tech stocks to your portfolio. Explore three ...